{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:52:01Z","timestamp":1789570321081,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Dupilumab and tralokinumab are FDA-approved biological agents for the treatment of atopic dermatitis (AD). This study analyzed tralokinumab-related adverse events (AEs) reported by healthcare professionals, utilizing data mined from the FDA Adverse Event Reporting System (FAERS). Furthermore, we compared the frequency of reports for common AEs with dupilumab or tralokinumab as the primary suspect, focusing on injection-site reactions, conjunctivitis, and keratitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Disproportionality analysis methods, including the reporting odds ratio (ROR), the Medicines and Healthcare products Regulatory Agency (MHRA) comprehensive method, the Bayesian confidence propagation neural network (BCPNN), and the Multi-item gamma Poisson shrinker (MGPS), were employed to quantify tralokinumab-associated AE signals. Then, the occurrence risk of common AEs between dupilumab and tralokinumab was further compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1,591,367 AE reports, 1,770 identified tralokinumab as the primary suspect. Tralokinumab-related AEs affected 25 System Organ Classes (SOC), with 49 significant disproportionality primary terms (PTs) consistently detected across all four algorithms. Notable potential AEs included eczema herpeticum, generalized exfoliative dermatitis, alopecia, skin exfoliation, and blepharitis. Most tralokinumab-related AEs occurred within the first month of treatment, with a median onset time of 37 days (interquartile range [IQR]: 13\u2013111 days). The reporting proportion of injection site reactions was significantly higher with dupilumab than with tralokinumab (p &amp;lt; 0.001). In contrast, tralokinumab was associated with a substantially higher reporting proportion of conjunctivitis (p = 0.001) and keratitis (p = 0.039).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified potential AE signals that could aid clinical monitoring and risk identification for tralokinumab. Additionally, close monitoring is warranted for dupilumab-associated injection site reactions and tralokinumab-associated conjunctivitis and keratitis throughout treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1769109","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:37:14Z","timestamp":1771828634000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database"],"prefix":"10.3389","volume":"17","author":[{"given":"Yueping","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Gaochun Traditional Chinese Medicine Hospital","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Air Force Hospital of Eastern Theater Command","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.clindermatol.2018.05.007","article-title":"Epidemiology of adult atopic dermatitis","volume":"36","author":"Sacotte","year":"2018","journal-title":"Clin Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100724","article-title":"Epidemiology of adult patients with atopic dermatitis in AWARE 1: A second international survey","volume":"16","author":"Maspero","year":"2023","journal-title":"World Allergy Organ J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13120","article-title":"The IL-13-OVOL1- FLG axis in atopic dermatitis","volume":"158","author":"Furue","year":"2019","journal-title":"Immunology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/1744666X.2020.1858802","article-title":"Therapeutic targeting of the IL-13 pathway in skin inflammation","volume":"17","author":"Tubau","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01659.x","article-title":"Preclinical Development of cat-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma","volume":"166","author":"May","year":"2012","journal-title":"Br J Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and Safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: The phase 3 ecztra 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21867","article-title":"Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: Pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials","volume":"187","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/37238","article-title":"The Prevalence of allergic diseases in Poland - the results of the PMSEAD study in relation to gender differences","volume":"23","author":"Liebhart","year":"2014","journal-title":"Adv Clin Exp Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"adv00160","DOI":"10.2340\/00015555-3510","article-title":"Prevalence and incidence of atopic dermatitis: A systematic review","volume":"100","author":"Bylund","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12784","article-title":"Adult eczema in Italy: Prevalence and associations with environmental factors","volume":"29","author":"Pesce","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20194660","article-title":"The roles of sex hormones in the course of atopic dermatitis","volume":"20","author":"Kanda","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/all.15811","article-title":"Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition","volume":"78","author":"Simpson","year":"2023","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01135-9","article-title":"Tralokinumab in atopic dermatitis: A profile of its use","volume":"42","author":"Blair","year":"2022","journal-title":"Clin Drug Investig"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17010","article-title":"Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata","volume":"63","author":"Tavoletti","year":"2024","journal-title":"Int J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000458","article-title":"Alopecia areata after treatment with dupilumab","volume":"30","author":"Yazdanyar","year":"2019","journal-title":"Dermatitis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.10.010","article-title":"Drug-induced alopecia after dupilumab therapy","volume":"5","author":"Flanagan","year":"2019","journal-title":"JAAD Case Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0542-7","article-title":"The changing landscape of alopecia areata: The therapeutic paradigm","volume":"34","author":"Renert-Yuval","year":"2017","journal-title":"Adv Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2016.1188076","article-title":"A novel therapeutic paradigm for patients with extensive alopecia areata","volume":"16","author":"Renert-Yuval","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16711","article-title":"Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata","volume":"179","author":"Darrigade","year":"2018","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e12869","DOI":"10.1111\/dth.12869","article-title":"Development of alopecia in patients treated with dupilumab","volume":"32","author":"Maloney","year":"2019","journal-title":"Dermatol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from the double-blind, randomized, multicentre, placebo- controlled phase III ecztra 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082867","article-title":"Skin barrier abnormalities and immune dysfunction in atopic dermatitis","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.923362","article-title":"The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjd.20810","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: Results from five tralokinumab clinical trials","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br J Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/14740338.2021.1939673","article-title":"Safety of dupilumab in patients with atopic dermatitis: Expert opinion","volume":"20","author":"Francuzik","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae344","article-title":"An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024","volume":"191","author":"Ardern-Jones","year":"2024","journal-title":"Br J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000003162","article-title":"Dupilumab-induced, tralokinumab-induced, and belantamab mafodotin-induced adverse ocular events-incidence, etiology, and management","volume":"42","author":"Mickevicius","year":"2023","journal-title":"Cornea"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2019.100550","article-title":"Dupilumab-associated blepharoconjunctivitis","volume":"16","author":"Paulose","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1159\/000534545","article-title":"Characterizing adverse events of biologic treatment of type 2 disease: A disproportionality analysis of the FDA adverse event reporting system","volume":"85","author":"Stack","year":"2023","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e15117","DOI":"10.1111\/dth15117","article-title":"Dupilumab-induced urticaria","volume":"34","author":"Mastorino","year":"2021","journal-title":"Dermatol Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.12-2-164","article-title":"The urticarias: Pathophysiology and management","volume":"12","author":"Grattan","year":"2012","journal-title":"Clin Med (Lond)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14625","article-title":"Erythroderma (exfoliative dermatitis). Part 1: underlying causes, clinical presentation, and pathogenesis","volume":"46","author":"Tso","year":"2021","journal-title":"Clin Exp Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1769109\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:37:15Z","timestamp":1771828635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1769109\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1769109"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1769109","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"article-number":"1769109"}}